| Drug NDC: | 63083-3014 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Libido Stim Liquescence 3014 |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Proprietary Name Base: | Libido Stim Liquescence |
| The base of the Brand/Proprietary name excluding its suffix. | |
| Proprietary Name Suffix: | 3014 |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Libido Stim Liquescence |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Professional Complementary Health Formulas |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE - 2 [hp_X]/118mL BERBERIS VULGARIS ROOT BARK - 3 [hp_X]/118mL BOS TAURUS OVARY - 16 [hp_X]/118mL BOS TAURUS TESTICLE - 16 [hp_X]/118mL BUFO BUFO CUTANEOUS GLAND - 6 [hp_X]/118mL CHASTE TREE FRUIT - 3 [hp_X]/118mL FERRIC CATION - 4 [hp_X]/118mL GLYCERIN - 1 [hp_X]/118mL IODINE - 3 [hp_X]/118mL PASSIFLORA INCARNATA FLOWERING TOP - 1 [hp_X]/118mL Load more... PULSATILLA MONTANA WHOLE - 4 [hp_X]/118mL SAW PALMETTO - 3 [hp_X]/118mL SELENIUM - 6 [hp_X]/118mL SODIUM CHLORIDE - 4 [hp_X]/118mL STRYCHNOS IGNATII SEED - 3 [hp_X]/118mL TURNERA DIFFUSA LEAF - 1 [hp_X]/118mL VANILLA BEAN - 1 [hp_X]/118mL YOHIMBINE - 3 [hp_X]/118mL ZINC VALERATE DIHYDRATE - 6 [hp_X]/118mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 15 Aug, 1984 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 18 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Professional Complementary Health Formulas |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | M0011718 N0000177913 N0000175597 N0000020074 N0000185370 N0000175629 N0000184306 N0000185001 M0000728 M0009417 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 043IPI2M0K 1TH8Q20J0U 66LZN1C747 PR4RXL6G2H Q59QU6N72Q 433OSF3U8A 91O4LML611 PDC6A3C0OX 9679TC07X4 CLF5YFS11O Load more... 24K790T39B J7WWH9M8QS H6241UJ22B 451W47IQ8X 1NM3M2487K 812R0W1I3K Q74T35078H 2Y49VWD90Q MN0RX54EQA |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Phosphate Chelating Activity [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Parenteral Iron Replacement [EPC] Phosphate Binder [EPC] Non-Standardized Chemical Allergen [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Iron [CS] Allergens [CS] Glycerol [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Dietary Proteins [CS] Food Additives [CS] Glycerol [CS] Increased Histamine Release [PE] Increased IgG Production [PE] Iron [CS] Non-Standardized Chemical Allergen [EPC] Non-Standardized Food Allergenic Extract [EPC] Parenteral Iron Replacement [EPC] Phosphate Binder [EPC] Phosphate Chelating Activity [MoA] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 63083-3014-4 | 118 mL in 1 BOTTLE, DROPPER (63083-3014-4) | 15 Aug, 1985 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.